RESEARCH TRIANGLE PARK, N.C., Sept. 6 /PRNewswire/ -- AlphaVax, a North Carolina-based vaccine company, presented an analysis of blinded results last week at the AIDS Vaccine 2006 meeting in Amsterdam from a Phase 1 clinical trial, run in collaboration with the Division of AIDS (DAIDS) at the National Institutes of Health (NIH) and the HIV Vaccine Trials Network (HVTN), evaluating a prototype HIV vaccine incorporating the HIV gag gene made using the company's alphavaccine technology.
